Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
Although the number of NDAs submitted to the FDA continue to rise year on year, the number of new molecular entities is on the decline, reflecting the increased cost of developing novel products.
